Prelude Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Prelude Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-1,500	Closed	-$26K	–	1930
2014 Q4	$26K	Buy	+1,500	New	+$21.4K	﹤0.01%	1661
2014 Q2	–	Sell	-16,100	Closed	-$216K	–	1901
2014 Q1	$216K	Buy	+16,100	New	+$173K	0.03%	702

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Prelude Capital Management's AVDL Position: Q1 2026 in Review

Prelude Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 31,694 shares — an estimated $683K sold.

Prelude Capital Management first reported a position in AVDL in Q1 2014 and held it in 16 quarters. The position peaked at $1.01M in Q2 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Prelude Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Prelude Capital Management sold 31,694 Avadel Pharmaceuticals shares in Q1 2026, an estimated $683K.
Prelude Capital Management first reported a position in Avadel Pharmaceuticals in Q1 2014 and held it in 16 quarters.
Prelude Capital Management's Avadel Pharmaceuticals position peaked at $1.01M in Q2 2024.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.